drugset / Trial / NCT06931652

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

NCT06931652

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenalidomide.

Timeline

Start
2025-09-22
Primary completion
2028-01
Completion
2030-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Epcoritamab Monoclonal antibody